Biora reports Q1 net loss $4.2M, completes BT-600 dosing, results expected late Q2

BIORA THERAPEUTICS, INC.

2024-Q1 EPS reported -$0.14 revenue$542,000

Net loss $4.2M ($0.14/share) vs $17.4M ($1.59) in Q1 2023; operating expenses $16.1M.
BT-600 Phase 1 trial fully dosed; SAD data showed colon delivery and lower plasma levels than oral tofacitinib.
BioJet platform animal studies demonstrate >15% bioavailability; partnering process targeting mid-2024.
Capital raised $19.8M new investment since Dec 2023, reduced $80M notes; $6M direct placement closed April 2024.
Topline BT-600 data expected late June 2024; NaviCap device data presented at DDW May 19.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIORA THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: net income Net loss was $4.2 million, EPS net loss per share was $0.14.

Period: the first quarter ended March 31, 2024
Net income: Net loss was $4.2 million
EPS: net loss per share was $0.14
Result: reported results

Exact text from the filing

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-060453

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.